

**510(k) SUBSTANTIAL EQUIVALENCE DETERMINATION
DECISION SUMMARY
INSTRUMENT ONLY TEMPLATE**

A. 510(k) Number:

K050057

B. Purpose for Submission:

Special 510(k) for a modification of sample stability claims

C. Manufacturer and Instrument Name:

Beckman Coulter Coulter® LH 750 Hematology Analyzer

D. Type of Test or Tests Performed:

The Coulter® LH 750 Hematology Analyzer is capable of providing a complete blood cell analysis (CBC) including a differential leukocyte cell count. This application is for the enumeration of leukocytes (WBC) and erythrocytes (RBC) in body fluids.

E. System Descriptions:

1. Device Description: The Coulter® LH 750 is a quantitative hematology analyzer with complete blood count (CBC), leukocyte differential, reticulocyte analysis, and nucleated RBC capability. It uses a reagent system consisting of isotonic diluent, lytic reagents to lyse the red cells without significantly affecting the white cells and an instrument cleaner. Additionally, the system includes reagents used for reticulocyte staining and analysis.

2. Principles of Operation: The Coulter® LH 750 uses the Coulter Principle for enumerating and sizing blood cells, automatic diluting and mixing for sample processing and a single beam photometer for hemoglobinometry. It utilizes Coulter VCS (volume, conductivity, and light scatter) technology for WBC differential analysis and classification and reticulocyte analysis.

For body fluid analysis, specimen is aspirated into the LH 700 via the manual mode and is diluted in separate WBC and RBC baths. The Coulter Method of counting cells is used to detect and measure changes in electrical resistance when a cell passes through a small aperture. The resistance generates an electrical pulse. The accumulation of electrical pulses are channelized, processed for coincidence correction, and multiplied by a calibration factor, yielding the WBC and RBC counts.

3. Modes of Operation:

Manual mode.

4. Specimen Identification:

Bar code scanner or manual input

5. Specimen Sampling and Handling:

Samples are manually mixed and handled

6. Calibration:

User calibration with whole blood and/or commercial calibration materials.

7. Quality Control:

Commercial quality control material is available for daily monitoring of the instrument.

8. Software:

FDA has reviewed applicant's Hazard Analysis and Software Development processes for this line of product types:

Yes or No The software was reviewed and cleared in a previous submission for this instrument (K032342)

F. Regulatory Information:

1. Regulation section:

21 CFR 864.5220

2. Classification:

II

3. Product code:

GKZ

4. Panel:

81

G. Intended Use:

1. Indication(s) for Use:

The LH 750 Series Body Fluid Application is a procedure for obtaining *in vitro* quantitative determinations of leukocytes (WBC) and erythrocytes (RBC) in cerebrospinal fluid, serous fluids, and synovial fluid, using a Coulter LH 700 Series Hematology Analyzer.

2. Special Conditions for Use Statement(s):

H. Substantial Equivalence Information:

1. Predicate Device Name(s) and 510(k) numbers:

Coulter LH 750 Body Fluids Application - K030606

2. Comparison with Predicate Device:

Similarities		
Item	Device	Predicate
Intended Use	The LH 750 Series Body Fluid Application is a procedure for obtaining <i>in vitro</i> quantitative determinations of leukocytes (WBC) and erythrocytes (RBC) in cerebrospinal fluid, serous fluids, and synovial fluid, using a Coulter LH 700 Series Hematology Analyzer.	same
Reagent systems	Coulter® LH 700 Series or Isoton 4 diluent, Coulter Lyse S® III or Lyse S® 4, Coulter Clenz®, Coulter Latron™ Primer and Latron Control, Coulter LH 700 Series Pak	same
Operating principle	Coulter principle and Coulter VCS	same

Differences		
Item	Device	Predicate
Sample stability	8 hrs for synovial fluid analysis and 8 hrs for serous fluids	1 hr for synovial fluid and 24 hrs for serous fluids

I. Special Control/Guidance Document Referenced (if applicable):

J. Performance Characteristics:

1. Analytical Performance:

a. Accuracy:

b. Precision/Reproducibility:

c. Linearity:

d. Carryover:

e. Interfering Substances:

2. Other Supportive Instrument Performance Data Not Covered Above:

As required for a Special 510(k), the Sponsor has provided a risk analysis as well as a Declaration of Conformity with Design Controls indicating that development activities were conducted under appropriate design controls procedures, and the overall product specifications were met.

K. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

L. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.